{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:18:20Z","timestamp":1773249500363,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bulcan.2025.10.009","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:12:11Z","timestamp":1766578331000},"page":"387-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Entretiens pharmaceutiques en onco-h\u00e9matologie et produits dits \u00ab\u00a0naturels\u00a0\u00bb\u00a0: un exemple illustr\u00e9 par le cannabidiol (CBD)"],"prefix":"10.1016","volume":"113","author":[{"given":"Lucas","family":"Fleta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre Valentin","family":"Laffitte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borhane","family":"Slama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valery","family":"Georges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bulcan.2025.10.009_bib0215","doi-asserted-by":"crossref","first-page":"e70126","DOI":"10.1002\/pds.70126","article-title":"Trends in the dispensing of oral anti-cancer medications across Australia over 10 years","volume":"34","author":"Leach","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.bulcan.2025.10.009_bib0220","doi-asserted-by":"crossref","first-page":"e2236380","DOI":"10.1001\/jamanetworkopen.2022.36380","article-title":"Factors associated with patients not receiving oral anticancer drugs","volume":"5","author":"Doshi","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.bulcan.2025.10.009_bib0225","article-title":"Contribution of pharmaceutical consultations to the management of oral anticancer agents","volume":"4","author":"Chevrier","year":"2018","journal-title":"JLE - Innovations & Th\u00e9rapeutiques en Oncologie"},{"key":"10.1016\/j.bulcan.2025.10.009_bib0230","unstructured":"Cancer IND. Strat\u00e9gie d\u00e9cennale de lutte contre les cancers 2021\u20132030 [Internet]. [cit\u00e9 27 mai 2025. Disponible sur\u00a0: https:\/\/www.cancer.fr\/l-institut-national-du-cancer\/la-strategie-de-lutte-contre-les-cancers-en-france\/strategie-decennale-de-lutte-contre-les-cancers-2021-2030]."},{"key":"10.1016\/j.bulcan.2025.10.009_bib0235","series-title":"Les entreprises du m\u00e9dicament\u00a0; TNS Sofrees [Internet]","year":"2011"},{"key":"10.1016\/j.bulcan.2025.10.009_bib0240","unstructured":"Recommandations S.F.P.O. Plantes et compl\u00e9ments alimentaires dans la prise en charge du patient atteint de cancer. Soci\u00e9t\u00e9 fran\u00e7aise de pharmacie oncologique."},{"key":"10.1016\/j.bulcan.2025.10.009_bib0245","unstructured":"Place des pratiques compl\u00e9mentaires dans les soins oncologiques de support\u00a0\u2013\u00a0AFSOS [Internet]. Association Francophone des Soins Oncologiques de Support. [cit\u00e9 27 mai 2025. Disponible sur\u00a0: https:\/\/www.afsos.org\/fiche-soin\/place-des-pratiques-complementaires-dans-les-soins-oncologiques-de-support\/]."},{"key":"10.1016\/j.bulcan.2025.10.009_bib0250","unstructured":"Question phytoth\u00e9rapie\u00a0\u2013\u00a0Volume 2 [Internet]. Association Francophone des Soins Oncologiques de Support. [cit\u00e9 27 mai 2025. Disponible sur\u00a0: https:\/\/www.afsos.org\/ressource-doc\/question-phytotherapie-volume-2\/]."},{"key":"10.1016\/j.bulcan.2025.10.009_bib0255","series-title":"\u00c9valuation des interactions m\u00e9dicamenteuses ou autres interactions entre le cannabis \u00e0 usage m\u00e9dical (CBD seul, THC seul et association de CBD\/THC) avec les traitements suivants utilis\u00e9s dans le cancer","year":"2021"},{"key":"10.1016\/j.bulcan.2025.10.009_bib0260","first-page":"19.200","article-title":"Mechanisms of action and pharmacokinetics of cannabis","volume":"25","author":"Chayasirisobhon","year":"2020","journal-title":"Perm J"},{"issue":"11","key":"10.1016\/j.bulcan.2025.10.009_bib0265","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bulcan.2025.10.009_bib0270","unstructured":"Arr\u00eat\u00e9 du 30 d\u00e9cembre 2021 portant application de l\u2019article R.\u00a05132-86 du Code de la sant\u00e9 publique [Internet]. [Disponible sur\u00a0: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000044793213]."},{"key":"10.1016\/j.bulcan.2025.10.009_bib0275","unstructured":"CBD et protoxyde d\u2019azote\u00a0: quels sont les niveaux de consommation chez les adultes en France\u00a0? [Internet]. [cit\u00e9 27 mai 2025. Disponible sur\u00a0: https:\/\/www.santepubliquefrance.fr\/les-actualites\/2023\/cbd-et-protoxyde-d-azote-quels-sont-les-niveaux-de-consommation-chez-les-adultes-en-france]."},{"issue":"3, Supplement","key":"10.1016\/j.bulcan.2025.10.009_bib0280","first-page":"S71","article-title":"Cannabidiol (CBD)\u00a0: analyse de produits \u00ab\u00a0CBD non pharmaceutiques\u00a0\u00bb disponibles en France","volume":"35","author":"Charuel","year":"2023","journal-title":"Toxicol Anal Clin"},{"issue":"5","key":"10.1016\/j.bulcan.2025.10.009_bib0285","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.therap.2022.02.001","article-title":"Pharmacologie du cannabidiol\u00a0: points de vigilance, cons\u00e9quences et risques chez l\u2019homme","volume":"77","author":"Micallef","year":"2022","journal-title":"Therapies"},{"issue":"12","key":"10.1016\/j.bulcan.2025.10.009_bib0290","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.bulcan.2025.10.009_bib0295","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/dmd.121.000734","article-title":"Comprehensive predictions of cytochrome P450 (P450)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent P450 inhibition in human liver microsomes","volume":"50","author":"Bansal","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.bulcan.2025.10.009_bib0300","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cpt.2973","article-title":"Evaluation of cytochrome P450-mediated cannabinoid-drug interactions in healthy adult participants","volume":"114","author":"Bansal","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bulcan.2025.10.009_bib0305","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/2193-1801-2-236","article-title":"A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC\/CBD oromucosal spray in healthy volunteers","volume":"2","author":"Stott","year":"2013","journal-title":"SpringerPlus"},{"issue":"2","key":"10.1016\/j.bulcan.2025.10.009_bib0310","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0897190020972208","article-title":"Reduction in tamoxifen metabolites endoxifen and N-desmethyltamoxifen with chronic administration of low dose cannabidiol: a CYP3A4 and CYP2D6 drug interaction","volume":"35","author":"Parihar","year":"2022","journal-title":"J Pharm Pract"},{"issue":"6","key":"10.1016\/j.bulcan.2025.10.009_bib0315","doi-asserted-by":"crossref","first-page":"e20193256","DOI":"10.1542\/peds.2019-3256","article-title":"Clinically significant drug-drug interaction between methadone and cannabidiol","volume":"145","author":"Madden","year":"2020","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.bulcan.2025.10.009_bib0320","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00406-019-01091-0","article-title":"Buprenorphine\u2013cannabis interaction in patients undergoing opioid maintenance therapy","volume":"271","author":"Vierke","year":"2021","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"10","key":"10.1016\/j.bulcan.2025.10.009_bib0325","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/ajt.15398","article-title":"Evidence of a clinically significant drug\u2013drug interaction between cannabidiol and tacrolimus","volume":"19","author":"Leino","year":"2019","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2025.10.009_bib0330","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/cpdd.1262","article-title":"Pharmacokinetic drug\u2013drug interaction with coadministration of cannabidiol and everolimus in a phase 1 healthy volunteer trial","volume":"12","author":"Wray","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"10.1016\/j.bulcan.2025.10.009_bib0335","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.3390\/jcm11051154","article-title":"Clinical relevance of drug interactions with cannabis: a systematic review","volume":"11","author":"Lopera","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.bulcan.2025.10.009_bib0340","doi-asserted-by":"crossref","first-page":"1282831","DOI":"10.3389\/fphar.2024.1282831","article-title":"Systematic review of drug\u2013drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis","volume":"15","author":"Nachnani","year":"2024","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.bulcan.2025.10.009_bib0345","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1089\/can.2021.0109","article-title":"Cannabidiol inhibits in vitro human liver microsomal metabolism of remdesivir","volume":"8","author":"Saraswat","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"issue":"9","key":"10.1016\/j.bulcan.2025.10.009_bib0350","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3390\/molecules29091981","article-title":"CBD in the treatment of epilepsy","volume":"29","author":"Borowicz-Reutt","year":"2024","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.bulcan.2025.10.009_bib0355","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3390\/pharmaceutics14122598","article-title":"Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020\u20132022)","volume":"14","author":"Souza","year":"2022","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.bulcan.2025.10.009_bib0360","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.3390\/cancers12092447","article-title":"Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome","volume":"12","author":"Bar-Sela","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bulcan.2025.10.009_bib0365","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1634\/theoncologist.2018-0383","article-title":"Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies","volume":"24","author":"Taha","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2025.10.009_bib0370","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise de pharmacie oncologique (SFPO) [Internet]. [cit\u00e9 4 juin 2025. Disponible sur\u00a0: https:\/\/oncolien.sfpo.com\/oncolien\/imatinib-glivec]."},{"key":"10.1016\/j.bulcan.2025.10.009_bib0375","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise de pharmacie oncologique (SFPO) [Internet]. [cit\u00e9 4 juin 2025. Disponible sur\u00a0: https:\/\/oncolien.sfpo.com\/oncolien\/dasatinib-sprycel]."},{"key":"10.1016\/j.bulcan.2025.10.009_bib0380","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise de pharmacie oncologique (SFPO) [Internet]. [cit\u00e9 4 juin 2025. Disponible sur\u00a0: https:\/\/oncolien.sfpo.com\/oncolien\/bosulif-bosutinib]."},{"key":"10.1016\/j.bulcan.2025.10.009_bib0385","unstructured":"SCEMBLIX 20\u00a0mg cp pellic\u00a0\u2013\u00a0VIDAL Hoptimal [Internet]. [cit\u00e9 4 juin 2025. Disponible sur\u00a0: https:\/\/hoptimal.vidal.fr\/medicament\/scemblix_20_mg_cp_pellic-239741.html#pharmacocinetique]."},{"key":"10.1016\/j.bulcan.2025.10.009_bib0390","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise de pharmacie oncologique (SFPO) [Internet]. [cit\u00e9 4 juin 2025. Disponible sur\u00a0: https:\/\/oncolien.sfpo.com\/oncolien\/nilotinib-tasigna]."},{"key":"10.1016\/j.bulcan.2025.10.009_bib0395","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise de pharmacie oncologique (SFPO) [Internet]. [cit\u00e9 4 juin 2025. Disponible sur\u00a0: https:\/\/oncolien.sfpo.com\/oncolien\/ponatinib-iclusig]."},{"issue":"12","key":"10.1016\/j.bulcan.2025.10.009_bib0400","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1080\/17512433.2022.2142114","article-title":"Cannabidiol drug interaction considerations for prescribers and pharmacists","volume":"15","author":"Graham","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.bulcan.2025.10.009_bib0405","unstructured":"Actualit\u00e9\u00a0\u2013\u00a0M\u00e9langer CBD et m\u00e9dicaments, ce n\u2019est jamais anodin [Internet]. ANSM. [cit\u00e9 5 juin 2025. Disponible sur\u00a0: https:\/\/ansm.sante.fr\/actualites\/melanger-cbd-et-medicaments-ce-nest-jamais-anodin]."},{"issue":"5","key":"10.1016\/j.bulcan.2025.10.009_bib0410","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.pharma.2021.01.009","article-title":"S\u00e9curisation du parcours de soins du patient sous th\u00e9rapie orale en oncologie\u00a0: exp\u00e9rimentation autour d\u2019un lien pharmaceutique h\u00f4pital\u2013ville","volume":"79","author":"Rubira","year":"2021","journal-title":"Ann Pharm Fr"},{"issue":"12","key":"10.1016\/j.bulcan.2025.10.009_bib0415","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bulcan.2024.10.005","article-title":"Mise en place et \u00e9valuation de la satisfaction du lien ville\u2013h\u00f4pital dans un service d\u2019oncologie m\u00e9dicale d\u2019un centre hospitalier universitaire\u00a0: une \u00e9tude prospective observationnelle","volume":"111","author":"Masse","year":"2024","journal-title":"Bull Cancer (Paris)"},{"issue":"9","key":"10.1016\/j.bulcan.2025.10.009_bib0210","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bulcan.2017.06.012","article-title":"Implication du pharmacien dans l\u2019accompagnement des patients sous anticanc\u00e9reux oraux\u00a0: \u00e9tat des lieux dans les centres de lutte contre le cancer (CLCC)","volume":"104","author":"Occhipinti","year":"2017","journal-title":"Bull Cancer (Paris)"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125005259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125005259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:15:25Z","timestamp":1773177325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125005259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0007455125005259"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.10.009","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Entretiens pharmaceutiques en onco-h\u00e9matologie et produits dits \u00ab\u00a0naturels\u00a0\u00bb\u00a0: un exemple illustr\u00e9 par le cannabidiol (CBD)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}